Alere i Influenza A & B Molecular. In minutes. ™ How could a rapid molecular result optimize patient care in your department? Clinicians often have to make immediate treatment decisions based only on signs and symptoms due to poor access to sensitive, rapid diagnostic tests and long turnaround times for laboratory PCR results. However, evidence suggests that clinical judgement alone has sensitivity rates between 29%1 and 36%.2 New highly sensitive rapid diagnostic tests for influenza are needed to help guide management in the clinical setting.1 Alere™ i combines the benefits of speed and accuracy on an easy to use system. You no longer need to compromise when testing your patients and making clinical decisions. n Lab-accurate results A rapid and accurate influenza result enables: Timely and targeted treatment Timely, targeted antiviral therapy is most effective closer to symptom onset.2 Antimicrobial Stewardship Operational/ Cost Efficiencies Improve antimicrobial stewardship by decreasing unnecessary antibiotic use.3,4 Boost operational/cost efficiency with fewer tests/investigations and faster time to discharge.5 Optimized Infection Control Optimize prompt infection control and reduce risk of onward transmissi

Other Molecular Systems Accurate Performance A new level of confidence in test sensitivity a'b Judgement1,2 Rapid Antigen6 90 100% l~0% 10 [20 [30 [40 [50 l~66 [70 [80 a. Comparison against RT-PCR or viral culture b. Comparison against culture Flu B 98.4% 99.4% PPA: Positive Percentage Agreement NPA: Negative Percentage Agreement Nasal Swab Direct or Product Name pr°duct C°de Sample Types in Viral Transport Media (VTM), - Nasopharyngeal Swab in VTM Alere™ i Influenza A & B 24 Test Kit 425-000 Time to Result <15 minutes Alere™ i Influenza...